Hologic Analyst Ratings
Evercore ISI Adjusts Price Target on Hologic to $76 From $78, Maintains In-line Rating
Hologic Analyst Ratings
Hologic Analyst Ratings
Argus Adjusts Price Target on Hologic to $95 From $89
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Community Health (CYH) and Hologic (HOLX)
Hologic Analyst Ratings
JP Morgan Maintains Overweight on Hologic, Raises Price Target to $91
UBS Adjusts Price Target on Hologic to $81 From $79, Maintains Neutral Rating
Needham: Reiterates the Hologic (HOLX.US) rating and adjusted from buy to buy, with a target price of $90.00.
Hologic Analyst Ratings
Needham Reiterates Buy on Hologic, Maintains $90 Price Target
Hologic's Strong Performance and Positive Outlook Reinforce Buy Rating
Hologic's Strategic Growth and Expansion: A 'Buy' Rating Analysis
Hologic (HOLX) Receives a Hold From RBC Capital
Analysts Conflicted on These Healthcare Names: Tilray (TLRY), Hologic (HOLX) and Bicycle Therapeutics (BCYC)
Needham: Reiterates the Hologic (HOLX.US) rating and adjusted from buy to buy, with a target price of $90.00.
Hologic Analyst Ratings
RBC Capital Sticks to Its Hold Rating for Hologic (HOLX)